GeneReach Biotechnology (4171) — Strategic Asset Allocation Index
GeneReach Biotechnology (4171) has a Strategic Asset Allocation Index of 46.0% as of June 2023. Strategic assets (PP&E of NT$434.94 Million plus long-term investments of NT$-) total NT$434.94 Million, measured against net assets of NT$946.49 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
GeneReach Biotechnology Strategic Asset Allocation Index (2017–2021)
This chart shows how GeneReach Biotechnology's Strategic Asset Allocation Index has evolved across 5 annual periods from 2017 to 2021. As of June 2023, the index stands at 46.0%, representing strategic assets of NT$434.94 Million against net assets of NT$946.49 Million TWD. Explore 4171 operating cash flow to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for GeneReach Biotechnology (2017–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for GeneReach Biotechnology from 2017 to 2021, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market cap of GeneReach Biotechnology.
| Year | SAAI | Strategic Assets (TWD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 36.5% | NT$397.11 Million | NT$397.11 Million | NT$- | NT$1.09 Billion | ▼ -8.5 pp |
| 2020 | 44.9% | NT$385.56 Million | NT$385.56 Million | NT$- | NT$857.76 Million | ▼ -5.7 pp |
| 2019 | 50.7% | NT$300.53 Million | NT$300.53 Million | NT$- | NT$593.05 Million | ▼ -15.4 pp |
| 2018 | 66.1% | NT$205.71 Million | NT$205.71 Million | NT$- | NT$311.15 Million | ▼ -7.8 pp |
| 2017 | 73.9% | NT$185.34 Million | NT$185.34 Million | NT$- | NT$250.63 Million | — |